HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
EYE ON CHINA
Sirona Biochem completes exclusive licensing agreement with leading anti-diabetic company in China, Wanbang Biopharmaceuticals
Sirona Biochem Corp. has entered into an exclusive licensing agreement with Wanbang Biopharmaceuticals. Sirona Biochem will provide an exclusive license to Wanbang Biopharma to develop and commercialize Sirona's anti-diabetic SGLT2 inhibitor in the People's Republic of China (PRC). In exchange for this license, Wanbang Biopharma will provide upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in the PRC.

In return for a robust licensing, milestone and royalty agreement, Sirona Biochem has transferred the responsibility for all funding, clinical development, regulatory requirements, manufacturing, sales and marketing of its SGLT2 inhibitor in China. Wanbang Biopharma will share all data generated through its clinical studies, significantly elevating the value of Sirona's SGLT2 inhibitor for licensing in the rest of the world.

Recent transaction values for SGLT2 Inhibitors include:

  • Empagliflozin, one of a two-compound licensing deal between Boehringer Ingelheim and Eli Lilly for at one time payment of EUR300 million and milestone payments of EUR625 million.

  • Dapagliflozin (Forxiga®), one of a two-compound licensing deal between Bristol Myers Squibb and AstraZeneca for upfront payment of US$100 million and milestone payments of up to US$1.25 billion

  • Bristol Myers Squibb and AstraZeneca expand licensing deal of dapagliflozin to include Japan; deal estimated to bring more than US$1 billion

In China alone, more than 90 million people suffer from diabetes, and this number is increasing at an alarming rate of 20% per year.

"We are proud to work with Wanbang Biopharma in the continued development of our SGLT2 inhibitor as treatment for this global epidemic." said Neil Belenkie, Chief Executive Officer of Sirona Biochem.

Source: Marketwired News

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy